Twist Bioscience Corp. Hits New 52-Week High at $66.00

Twist Bioscience Corp. has reached a significant milestone by hitting a new 52-week high of USD 66.00 on April 22, 2026. This achievement highlights the company's notable performance within the Pharmaceuticals & Biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 2,760 million. Over the past year, Twist Bioscience Corp. has demonstrated a performance increase of 26.37%, although it remains below the S&P 500's performance of 34.99%. The company's financial metrics reveal a challenging landscape, as it currently operates at a loss, reflected in its price-to-earnings ratio, which is not applicable. Additionally, the company has a price-to-book ratio of 6.05, indicating its valuation relative to its book value. Despite a debt-to-equity ratio of -0.41 and a return on equity of -16.79%, the recent price movement underscores the stock's resilience and the potential for growth within the competitive biotechnology market. The previous 52-week low for Twist Bioscience Corp. was recorded at USD 23.50, marking a substantial increase in its stock value.